AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$73.91
neg -0.72
-0.96%
Today's Range: 73.84 - 74.75 | ABBV Avg Daily Volume: 5,485,700
Last Update: 07/24/17 - 4:01 PM EDT
Volume: 5,407,634
YTD Performance: 19.18%
Open: $74.63
Previous Close: $74.63
52 Week Range: $55.06 - $75.04
Oustanding Shares: 1,591,540,513
Market Cap: 115,816,403,131
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 4 4 4
Moderate Buy 1 1 1 1
Hold 6 8 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.08 2.31 2.36 2.36
Latest Dividend: 0.64
Latest Dividend Yield: 3.46%
Dividend Ex-Date: 07/12/17
Price Earnings Ratio: 14.66
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
14.66 18.90 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.94% 16.81% 38.20%
GROWTH 12 Mo 3 Yr CAGR
Revenue 12.20 0.40 0.11
Net Income 15.70 0.40 0.13
EPS 16.00 0.40 0.12
Earnings for ABBV:
EBITDA 10.57B
Revenue 25.64B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.40 $1.41 $5.52 $6.55
Number of Analysts 10 8 11 11
High Estimate $1.42 $1.46 $5.57 $6.99
Low Estimate $1.35 $1.37 $5.47 $6.26
Prior Year $1.26 $1.21 $4.82 $5.52
Growth Rate (Year over Year) 11.27% 16.32% 14.60% 18.65%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Gary Morrow

 | Jul 20, 2017 | 12:57 PM EDT
Today's breakout could carry the stock sharply higher.
RMPIA
By

Bret Jensen

 | May 3, 2017 | 11:40 AM EDT
How did Celgene, AbbVie and Gilead fare last quarter?
RMPIA
By

Jim Cramer

 | Apr 27, 2017 | 3:48 PM EDT
It doesn't look like Washington will be much help.
By

Gary Morrow

 | Apr 27, 2017 | 1:50 PM EDT
ABBV is now set up well for more upside.
By

Bret Jensen

 | Apr 27, 2017 | 10:09 AM EDT
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb (BMY) is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily surpassed estimates, powered by Opdivo growth. AbbVie (ABBV) also is up nicely. Its oncology product Imbruvica posted an almost 45% rise in year-over-year sales while Humira continues to see sales growth in the mid-teens
RMPIA
By

Bret Jensen

 | Apr 27, 2017 | 8:49 AM EDT
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today.
RMPIA
By

Bret Jensen

 | Apr 26, 2017 | 11:30 AM EDT
Biotech investors should keep a close eye on the progress in this huge potential market.
By

Bret Jensen

 | Apr 12, 2017 | 11:00 AM EDT
Acadia and Neurocrine both have catalysts for growth; buy any weakness.
RMPIA
By

Jim Cramer

 | Apr 3, 2017 | 4:04 PM EDT
It's pretty normal to have profit-taking after such a strong first quarter.

bullishAbbvie added to Conviction Buy List at Goldman

Mar 10, 2017 | 6:51 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. $80 price target. Company is growing faster than its peers, but trades at a discount.
Ahead of Wednesday's earnings report(pre open)GD is on its way to its best close of the ye...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.